Detection of disease recurrence in differentiated thyroid cancer

Minerva Chirurgica

Volumn 65, Issue 1, 2010, Pages 101-116

  Shin, J J ^a   Milas, M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Risk management; Thyroglobulin; Thyroid neoplasms; Ultrasonography

Indexed keywords

ALGORITHM; HUMAN; PATHOLOGY; REVIEW; THYROID TUMOR; TUMOR RECURRENCE;

ALGORITHMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; THYROID NEOPLASMS;

EID: 77952929617     PISSN: 00264733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295; 2l64-7.
2. Burke JP, Hay ID, Dignan F, Goellner JR, Achenbach SJ, Oberg AL et al. Long-term trends in thyroid carcinoma: a population-based study in Olmsted County, Minnesota, 1935-1999. Mayo Clin Proc 2005;80; 753-8.
3. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009;115:3801-7.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
5. Pacini F. Follow-up of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2002;29 (Suppl 2) : S492-6.
6. Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J et al. Initial results from a prospec-tive cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U. S. and German thyroid cancer study group. An American college of surgeons commission on cancer patient care evaluation study. Cancer 2000;89:202-17.
7. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medicai therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.
8. Tuttle RM, Leboeuf R, Martorella AJ. Papillary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin North Am 2007;36:753-78.
9. Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, Levy EG et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. Arch Intern Med 1996;156:2165-72.
10. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42.
11. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.
12. Aygun N. Imaging of recurrent thyroid cancer. Otolaryngol Clin North Am 2008;41:1095-106.
13. Tuttle RM, Leboeuf R. Follow up approaches in thyroid cancer: a risk adapted paradigm. Endocrinol Metab Clin North Am 2008;37:419-35. (Pubitemid 351698090)
14. Gupta M, Chia SY. Circulating thyroid cancer markers. Curr Opin Endocrinol Diabetes Obes 2007;14:383-8.
15. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma: a population-based study of 15, 698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 1997;79:564-73.
16. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-63.
17. Dean DS, Hay ID. Prognostic indicatore in differentiated thyroid carcinoma. Cancer Control 2000;7:229-39.
18. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M, editore. American Joint Committee on Cancer Staging Manual. 6th edition. New York, NY: Springer-Verlag; 2002.
19. Byar DP, Green SB, Dor P, Williams ED, Colon J, van Gilse HA et al. A prognostic index for thyroid carcinoma: a study of the E. O. R. T. C. Thyroid Cancer Cooperative Group. Eur J Cancer 1979;15:1033-41.
20. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic sco-ring system. Surgery 1987;102:1088-95.
21. Cady B, Rossi R. An expanded view of risk-group defi-nition in differentiated thyroid carcinoma. Surgery 1988;104:947-53.
22. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993;114:1050-8.
23. Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 1995;118:1131-8.
24. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid abla-tion? J Clin Endocrinol Metab 2002;87:1490-8.
25. Woyach JA, Shah MH. New therapeutic advances in the management of progressive thyroid cancer. Endocr Relat Cancer 2009;16:715-31.
26. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K et al. Phase II trial of sora-fenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-9.
27. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:31-42.
28. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708-13.
29. Droz J, Baudin E, Medvedev V, Delord J, Rane M, Kloos R et al. Activity of irofulven (IROF) combined with capecitabine (CAPE) in patients (pts) with advanced thyroid carcinoma: phase II international multi-center study (preliminary results). J Clin Oncol 24 Suppl abstract 15511.
30. Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D et al. Phase II study of celecoxib in meta-static differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91:2201-4.
31. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-84.
32. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005;90:5566-75.
33. Spencer CA, LoPresti JS. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat Clin Pract Endocrinol Metab 2008;4:223-33.
34. Feldt-Rasmussen U, Peterson PH, Date J, Madsen CM. Sequential changes in serum thyroglobulin (Tg) and its autoantibodies (TgAb) following subtotal thyroidectomy of patients with preoperatively detectable TgAb. Clin Endocrinol (Oxf) 1980;12:29-38.
35. Spencer CA. Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab 2004;89:3702-4.
36. Giovanella L. Highly sensitive thyroglobulin measure-ments in differentiated thyroid carcinoma management. Clin Chem Lab Med 2008;46:1067-73.
37. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:1121-7.
38. Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003;139:346-51.
39. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-41. (Pubitemid 36623351)
40. Robbins RJ, Chon JT, Fleisher M, Larson S, Tuttle RM. Is the serum thyroglobulin response to recombinant human TSH sufficient, by itself, to monitor for residuai thyroid carcinoma? J Clin Endocrinol Metab 2002;87:3242-7.
41. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877-85.
42. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the post-surgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001;86:5686-90.
43. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002;87:1499-501.
44. Iervasi A, fervasi G, Ferdeghini M, Solimeo C, Bottoni A, Rossi L et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf) 2007;67:434-41.
45. Mazzaferri EL. Will highly sensitive thyroglobulin assays change the management of thyroid cancer? Clin Endocrinol (Oxf) 2007;67:321-3.
46. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000;85:175-8.
47. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C. Recombinant human thyrotropin-stimu-lated serum thyroglobulin combined with neck ultra-sonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003;88:3668-73.
48. Wartofsky L. Using baseline and recombinant human TSH-stimulating Tg measurements to manage thyroid cancer without diagnostic 131-I scanning. J Clin Endocrinol Metab 2002;87:1486-9.
49. Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodine on the uptake of ablative dose of iodine-131. Thyroid 1994;4:49-54.
50. Mandel SJ, Shankar LK, Bernard F, Yamamoto A, Alavi A. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 2001;26:6-9.
51. Spanu A, Solinas ME, Chessa F, Sanna D, Nuvoli S, Madeddu G. 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incrementai value versus planar imaging. J Nucl Med 2009;50:184-90.
52. Hilditch TE, Dempsey MF, Bolster AA, McMenemin RM, Reed NS. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Eur J Nucl Med Mol Imaging 2002;29:783-8.
53. Frasoldati A, Pesenti M, Gallo M, Careggio A, Salvo D, Valcavi R. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 2003;97:90-6.
54. Lee YH, Lee NJ, Kim JH, Song JJ. US diagnosis of cervical recurrence in patients operated on thyroid cancer: sonographic features and clinical significance. Auris Nasus Larynx 2007;34:213-9.
55. Seiboth L, Van Nostrand D, Wartofsky L, Ousman Y, Jonklaas J, Buder C et al. Utility of PET/neck MRI digitai fusion images in the management of recurrent or persistent thyroid cancer. Thyroid 2008;18:103-11.
56. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987;28:910-4.
57. Finkelstein SE, Grigsby PW, Siegel BA, Dehdashti F, Moley JF, Hall BL. Combined [18F]fluorodeoxyglucose position emission tomography and computed tomo-graphy (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Ann Surg Oncol 2008;15:286-92.
58. Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD et al. [18F]-2-fluoro-2-deoxy-D-glucose posi-tron emission tomography localizes residuai thyroid cancer in patients with negative diagnostic (131) I who-le body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999;84:2291-302.
59. Schlüter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001;42:71-6.
60. Hall NC, Kloos RT. PET imaging in differentiated thyroid cancer: where does it fit and how do we use it? Arq Bras Endocrinol Metabol 2007;51:793-805.
61. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006;91:498-505.
62. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000;85:1107-113.
63. Mazzaferri EL. Changing paradigms in the follow-up of patients with differentiated thyroid cancer: an alternative to [18F]fluorodeoxyglucose positron emission tomographic scanning. Endocr Pract 2003;9:324-6.
64. Petrich T, Borner AR, Otto D, Hofmann M, Knapp WH. Influence of rhTSH on [(18F)]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2002;29:641-7.
65. Dong MJ, Liu ZF, Zhao K, Ruan LX, Wang GL, Yang SY et al. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta analysis. Nucl Med Commun 2009;30:639-50.
66. Phan HT, Jager PL, Plukker JT, Wolffenbuttel BH, Dierckx RA, Links TP. Comparison of 11C-methionine PET and 18F-fluorodeoxyglucose PET in differentiated thyroid cancer. Nucl Med Commun 2008;29:711-6.
67. Ditkoff BA, Marvin MR, Yemul S, Shi YJ, Chabot J, Feind C et al. Detection of circulating thyroid cells in peripheral blood. Surgery 1996;120:959-65.
68. Tallini G, Ghossein RA, Emanuel J, Gill J, Kinder B, Dimich AB et al. Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease. J Clin Oncol 1998;16:1158-66.
69. Ringel MD, Ladenson PW, Levine MA. Molecular diagnosis of residuai and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. J Clin Endocrinol Metab 1998;83:4435-42.
70. Bojunga J, Röddiger S, Stanisch M, Kusterer K, Kurek R, Renneberg H et al. Molecular detection of thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease by RT-PCR. Br J Cancer 2000;82:1650-5.
71. Wingo ST, Ringel MD, Anderson JS, Patel AD, Lukes YD, Djuh YY et al. Quantitative reverse transcription-PCR measurement of thyroglobulin mRNA in peripheral blood of healthy subjects. Clin Chem 1999;45 (6 Pt 1) ; 785-9.
72. Ringel MD, Balducci-Silano PL, Anderson JS, Spencer CA, Silverman J, Sparling YH et al. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma. J Clin Endocrinol Metab 1999;84:4037-42.
73. Elisei R, Vivaldi A, Agate L, Molinaro E, Nencetti C, Grasso L et al. Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients. J Clin Endocrinol Metab 2004;89:33-9.
74. Gupta MK, Taguba L, Arciaga R, Siperstein A, Faiman C, Menta A et al. Detection of circulating thyroid cancer cells by reverse transcription-PCR for thyroid-sti-mulating hormone receptor and thyroglobulin: the importance of primer selection. Clin Chem 2002;48:1862-5.
75. Savagner F, Rodien P, Reynier P, Rohmer V, Bigorgne JC, Malthiery Y. Analysis of Tg transcripts by real-time RT-PCR in the blood of thyroid cancer patients. J Clin Endocrinol Metab 2002;87:635-9.
76. Chinnappa P, Taguba L, Arciaga R, Faiman C, Siperstein A, Menta AE et al. Detection of thyrotropin-receptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease: sensitive and specific markers for thyroid cancer. J Clin Endocrinol Metab 2004;89:3705-9.
77. Chia SY, Milas M, Reddy SK, Siperstein A, Skugor M, Bramarci J et al. Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer. J Clin Endicrinol Metab 2007;92:468-75.
78. Wagner K, Arciaga R, Siperstein A, Milas M, Warshawsky I, Sethu S et al. Thyrotropin receptor/thyroglobulin messenger ribonucleic acid in peripheral blood and fine-needle aspiration cytology: diagnostic synergy for detecting thyroid cancer. J Clin Endocrinol Metab 2005;90:1921-4.
79. Milas M, Mazzaglia P, Chia SY, Skugor M, Berber E, Reddy S et al. The utility of peripheral thyrotropin mRNA in the diagnosis of follicular neoplasms and surveillan-ce of thyroid cancers. Surgery 2007;141:137-46.
80. Barbosa GF, Milas M. Peripheral thyrotropin receptor mRNA as a novel marker for differentiated thyroid cancer diagnosis and surveillance. Expert Rev Anticancer Ther 2008;8:1415-24.
81. Milas M, Barbosa GF, Mitchell J, Berber E, Siperstein A, Gupta M. Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer. Ann Surg Oncol 2009;16:473-80.
82. Cleveland Clinic Reference Laboratory. Search Directory of Test Information [Homepage]. [Accessed 2009 December 31; cited 2010 January 12]. Available at: http://referencelab.clevelandclinic.org.
83. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003;63:4561-7.
84. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
85. Namba, H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393-7.
86. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and ana-plastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;10:2761-5.
87. Xing M, Tufano RP, Turafo. AP, Basaria S, Ewertz M, Rosenbaum E et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 2004;89:2867-72.
88. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M et al. BRAF (V599E) mutation is the lea-ding genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004;89:24l4-20.
89. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004;45:818-21.
90. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vincentini L et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 2004;61:239-43.
91. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ et al. BRAF mutation prediets a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-9.
92. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742-62.
93. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conven-tional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005;63:588-93.
94. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventio-nal papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006;65:364-8.
95. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I-targeting to the membrane 2006;13:257-69.
96. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006;13:455-64.
97. Vdovichenko KK, Markova SI, Belokhvostov AS. Mutant form of BRAF gene in blood plasma of cancer patients. Ann N Y Acad Sci 2004;1022:228-231.
98. Cradic KW, Milosevic D, Rosenberg AM, Erickson LA, Mclver B, Grebe SK. Mutant BRAF (T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J Clin Endocrinol Metab 2009;94:5001-9.
99. Tutde RM. Risk-adapted management of thyroid cancer. Endocr Pract 2008;14:764-74.
100. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803.